REDWOOD CITY, CA, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY) ("Biotricity" or the "Company”), an innovative Technology-as-a-Service (TaaS) company committed to redefining the landscape of the healthcare industry with …

… November 7, 2025 ANI Pharmaceuticals, Inc. beats earnings expectations … prefilled syringe in the second quarter, reducing administration steps for … reconciliation to our GAAP expenditures. Non-GAAP cost of … in volume versus the second quarter of ’25. And …

… the second quarter of this fiscal year. The Hyderabad-based drugmaker’s consolidated … compounds, such as novel active pharmaceutical ingredients (APIs) or intermediates … is currently executing three capital expenditure programmes, with an estimated …

… at ₹591 crore for the second quarter of the financial year 2025 … quarter, the R&D expenditure rose by 8 per cent … Top 500 brands in Indian Pharmaceuticals Market, with 15 brands … 21, 2025 respectively. Torrent Pharmaceuticals is a specialty-focused company …

Total Company Revenue increased 13.4% to $522.9 million in the third quarter of 2025 from $461.1 million in the third quarter of 2024; Revenue from the Digital Health reportable segment (inclusive of intersegment revenue) increased 51.6% to $24.8 million …

… pharma major has posted strong financial performance during the second quarter … performances ever in this second quarter of FY26. We continue … ’s research and development expenditure went up by 13.6 … .2% of sales) for Q2 FY2025. Lupin received approval for …

… second largest Indian pharma company with revenues of … well as profits during the second quarter ended September 2025. Its … and managing director, said: “Q2 has been another steady quarter … D expenditure touched to Rs. 414 crore during the second quarter ended …

Shares of pharma major Lupin rose 2.3% … .6%. Key expense highlights for Q2 FY26 included personnel cost at … ,730.4 crore, and capital expenditure for the quarter was Rs … strongest performances ever in this second quarter of FY26. We continue to …

Apollo Hospitals Enterprise Ltd's September-quarter financial performance beat Street expectations, as gains in its specialty care like cardiac, oncology, neurosciences, gastroenterology and orthopaedics (CONGO) outweighed the dip in seasonal …

Pharmaceutical company Lupin Ltd on Thursday ( … ₹5,672.7 crore in Q2 FY25. Earnings before interest, tax … ,730.4 crore, while capital expenditure for the quarter was ₹347 … strongest performances ever in this second quarter of FY26. We continue to …